• Saves up to six months on compliant software validation in biopharmaceutical quality control.
• Reduces analysis time for biotherapeutic peptides and proteins by 20%.
• Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques.

Waters Corporation  announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis from Multi-Angle Light Scattering (MALS) and differential Refractive Index (RI) instruments in its Wyatt Technology™ Portfolio. This integration expands the scope of critical quality attributes that a biopharmaceutical laboratory can manage using Empower Software. Additionally, this advancement will simplify the process and digital footprint of acquiring and submitting compliant data to regulatory authorities – from biologics development through QC – saving customers up to six months of software validation time.

Empower Software is the industry’s most established and compliant-ready chromatography data system (CDS), widely adopted globally and used to submit data for more than 80% of novel drugs to regulatory authorities.⁴ The new integration unlocks the ability to use MALS techniques in quality control for biotherapeutics, improving efficiency and Good Manufacturing Practices (GMP) readiness, while reducing end-user training in compliant settings.

“Today’s launch of Empower for Multi-Angle Light Scattering Detectors underscores our commitment from the Wyatt acquisition to integrate advanced analytical technologies into our Empower CDS ecosystem,” said Dr. Udit Batra, President & CEO, Waters Corporation. “Specifically, MALS supported on Empower Software reveals high molecular weight species that are not visible to other detectors – reducing the risk of erroneous results in biotherapeutic quality control. By combining the strengths of compliant software with deep analytical light scattering instrumentation, we are providing customers with a unified solution that enhances productivity and data accuracy – ultimately supporting high-volume QC testing to ensure the safety of life-saving biologic therapies for patients.”

The integration of the DAWN™, miniDAWN™, and OptiLab™ Detectors will enable the measurement of more critical quality attributes of peptides and proteins in a single run, reducing analysis time by 20% and providing earlier insights into the stability, safety, and efficacy of biologics.

"As a Contract Development and Manufacturing Organization (CDMO), we anticipate that MALS on Empower Software will enhance our service offerings,” said William Wittbold, Senior Director of Operations, at Pace Analytical. “The detailed MALS data is essential for understanding complex biotherapeutics. Combined with the reliability of Empower Software, we believe this integration will deliver exceptional value to our customers, ensuring our drug development partners receive the highest quality results."